diflomotecan
Small moleculeexperimental
Diflomotecan is a chemotherapeutic agent that is a topoisomerase inhibitor (Top1). It varies from other camptothecin based Top1 inhibitors like topotecan in having a 7-membered E-ring. The oxepan-2-one ring in the homocamptothecin analogues is more stable in plasma compared to the 6-membered lactone in camptothecin. Diflomotecan was the first homocamptothecin to enter clinical trials and was previously in phase II for treating patients with sensitive small cell lung cancer (SCLC). — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2004 (NCT00080015)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Topoisomerase IINHIBITOR
Topoisomerase I inhibitor
- DNA topoisomerase IINHIBITOR
DNA topoisomerase I inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC[C@@]1(O)CC(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(F)c(F)cc3nc2-1- Mol. weight
- 398.37 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDiflomotecan ↗
- ChEMBLCHEMBL306280 ↗
Also known as
- bn80915
- bn 80915
- bn-80915
- diflomotecan
- diflomotecan
- diflomotecan
- diflomotecan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00080015 | Phase 2 | Mar 1, 2004 | Institut Gustave Roussy, Ipsen |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institut Gustave Roussy | Academic/Hospital | 1 | 0 | 1 | 2004 |
| Ipsen | For profit | 1 | 1 | 1 | 2004 |
2 organizations
Page 1 / 1